Please assess the completion status of the following clinical trial:

Trial Title: Study of ZSP1273 in Patients With Acute Uncomplicated Influenza A

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~1. Males and female subjects between 18-65 years (Both inclusive).~2. Patients with a diagnosis of influenza virus A infection confirmed by all of the following:~   * Positive Rapid Antigen Test (RAT) with throat swabs;and~  * Fever≥38.0ºC (axillary) in the predose examinations;and~  * At least one of the following general systemic symptoms and respiratory symptoms respectively associated with influenza are present with a severity of moderate or greater:~     * General systemic symptoms:Headache,Feverishness or chills,Muscle or joint pain,Fatigue;~    * Respiratory symptoms:Cough,Sore throat,Nasal congestion.~3. The time interval between the onset of symptoms and the enrollment is≤48 hours. The onset of symptoms is defined as:~   * Time of the first increase in body temperature(axillary temperature≥38.0ºC),or~  * Time when the patient experiences at least one general or respiratory symptom.~4. Subjects who agree to use an appropriate method of contraception during the study and up to 6 months after drug withdrawal.~5. Signature of a dated Informed Consent Form (ICF) indicating that the subject has been informed of all the relevant aspects(including adverse events) of the trial prior to enrollment.~Exclusion Criteria:~1. Known hypersensitivity and/or allergy to some drugs and food,especially for the composition that is similar to ZSP1273;~2. Dysphagia or any medical history in gastrointestinal that interferes with the absorption of drugs.~3. Use of the following medications within 7 days prior to screening:~   * Influenza antiviral medication:oseltamivir,peramivir,famivir,abidol,amantadine or rimantadine.~  * Chinese patent medicine or herbal medicine with antiviral effect.~4. Patients who have received influenza vaccine within 6 months prior to enrollment.~5. Presence of clinically significant abnormalities in ECG .~6. Chest X - ray examination confirmed bronchitis,pneumonia,pleural effusion or pulmonary interstitial lesions.~7. Patients who have experienced respiratory tract infection,Otitis media,nasosinusitis.~8. White blood cells(WBC)\>10.0×109/L at screening.~9. Subject who produces purulent sputum or has suppurative tonsillitis.~10. Patients with severe or uncontrollable underlying diseases:blood disorders,severe chronic obstructive pulmonary disease(COPD),liver disorders(ALT or AST≥3 ULN,total bilirubin≥1.5 ULN),kidney disorders(serum creatinine\>177μmol/L or 2mg/dL),chronic congestive heart failure(NYHA III-IV),mental disorders.~11. Immunodeficiency,including malignant tumor,organ or marrow transplant,human immunodeficiency virus \[HIV\] infection,or patients receiving immunosuppressant therapy 3 months prior to enrollment.~12. Concomitant therapy with aspirin or salicylic acid.~13. Morbid obesity(Body mass index \[BMI\]≥30kg/m2).~14. Known history of alcohol abuse or drug abuse.~15. Pregnancy or breastfeeding at screening and during the study.All female subjects of childbearing potential must have a negative urine pregnancy test at screening and during the trial.~16. Have received any other investigational products within 3 months prior to dosing.~17. Subjects who should not be included in the study in the opinion of the Investigator.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- ZSP1273-200 mg BID (Type: EXPERIMENTAL): Subjects will receive 10 doses of ZSP1273 200mg along with placebo twice daily (BID) with approximately 12 hour (+/- 2) intervals, over 5 days.
- ZSP1273-400 mg BID (Type: EXPERIMENTAL): Subjects will receive 10 doses of ZSP1273 400mg（200mg\*2) along with placebo twice daily (BID) with approximately 12 hour (+/- 2) intervals, over 5 days.
- ZSP1273-600 mg QD (Type: EXPERIMENTAL): Subjects will receive 5 doses of ZSP1273 600mg （200mg \*3) and 5 doses of placebo respectively for 5 days.The interval between ZSP1273 and placebo is approximately 12 hour (+/- 2) .
- Placebo (Type: PLACEBO_COMPARATOR): Subjects will receive 10 doses of matching placebo of ZSP1273 twice daily (BID) with approximately 12 hour (+/- 2) intervals, over 5 days.

Based on this trial design, predict the completion outcome and termination type (if applicable).